. 2019 Mar 13;12(Suppl 2):37. doi: 10.1186/s12920-019-0481-z

Table 2.

Rates of genotypes of analyzed genes in groups of patients with optimal and non-optimal response to TKI therapy

Gene and reference SNP	Reference allele	Variant allele		Patients with optimal response at 6 months (n = 32)			Patients with non-optimal response at 6 months (n = 30)			р-value
ANKRD35 rs11579366	G	C	genotype	G/G	G/C	C/C	G/G	G/C	C/C	0,16
ANKRD35 rs11579366	G	C	rate, %	9	50	41	29	39	32	0,16
DNAH9 rs1990236	G	A	genotype	G/G	G/A	A/A	G/G	G/A	A/A	0,33
DNAH9 rs1990236	G	A	rate, %	72	22	6	57	39	4	0,33
MAGEC1 rs176037	C	T	genotype	C/C	C/T	T/T	C/C	C/T	T/T	0,68
MAGEC1 rs176037	C	T	rate, %	53	20	27	41	32	27	0,68
TOX3 rs10653661	A	ATTTCT	genotype	A/A	A/ ATTTCT	ATTTCT/ ATTTCT	A/A	A/ ATTTCT	ATTTCT/ ATTTCT	0,87
TOX3 rs10653661	A	ATTTCT	rate, %	22	56	22	23	50	27	0,87
THSD1 rs3803264	G	A	genotype	G/G	G/A	A/A	G/G	G/A	A/A	0,38
THSD1 rs3803264	G	A	rate, %	6	44	50	12	27	61	0,38
MORN2 rs3099950	G	A	genotype	G/G	G/A	A/A	G/G	G/A	A/A	0,48
MORN2 rs3099950	G	A	rate, %	69	31	0	77	23	0	0,48
PTCRA rs9471966	G	A	genotype	G/G	G/A	A/A	G/G	G/A	A/A	0,88
PTCRA rs9471966	G	A	rate, %	56	38	6	50	43	7	0,88

SNP single nucleotide polymorphism